Surgery, chemotherapy, radiation therapy, and immunotherapy are potential therapeutic approaches used for the treatment of various malignant and metastatic cancers. Despite adverse side effects and pain, surgery and chemotherapy are the primary treatment modalities for cancer. However, patients at late stages of cancer or post-surgery cancer recurrence remain hard to cure [1]. Immunotherapy selectively targets and eliminates cancer cells primarily by boosting the immune system. It eventually helps to ameliorate tumours, reduces metastasis, and tumour recurrence compared to other treatments [2]. Immunotherapy either suppresses or activates the immune system clinically under diseased conditions since both immunosuppression and immune evasion are strategies adopted by the cancer cells for growth and metastasis [2].

Tumours become metastatic by invading the adjacent healthy tissues. Ultimately, malignant tumours spread to various tissues/organs of the body. Unlike healthy cells, cancer cells express or over-express abnormal proteins, i.e. tumour-associated antigens (TAAs), due to their genetic instability [3–5]. Adoptive chimeric antigen receptor T-cell (CAR-T) based therapy is under clinical trial for recurring cancers and various metastatic cancers such as haematological malignancies [6], metastatic neuroblastoma [6, 7], glioblastoma [8], and prostate cancer [9]. Recently, the US Food and Drug Administration (FDA) has approved CD19-targeting CAR-T-cells for clinical use [10]. However, solid tumours possess complex mechanisms, which hamper the infiltration of immune cells that, in turn, promote immune suppression in the tumour microenvironment (TME). It eventually limits the anti-tumour efficacy of CAR-T and CAR-natural killer (NK) cells against solid tumours. Hence, approaches involving a combination of chemotherapy, radiotherapy, and immune checkpoint inhibitors are recommended, which will enhance the efficacy of CAR-T and CAR-NK cells against solid tumours [11].

The strategy of targeting TAA includes the administration of whole protein antigen [12], mature peptide epitopes [13], cell lysate [14], and adoptive transfer schemes [15]. CTL4 is a receptor protein expressed on the surface of T regulatory cells that downregulates the immune response [16]. Therefore, a monoclonal antibody (ipilimumab) has been developed and approved for cancer therapy [17]. Similarly, monoclonal antibodies, which target various receptors and ligands [e.g., programmed death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1)], were approved for melanoma [18], non-small cell lung cancer (NSCLC) [19], head and neck squamous cell cancer (HNSCC), urothelial cancer, classical Hodgkin’s lymphoma, and renal cell cancer [20]. Immunotherapy patients showed prolonged control over cancer than other treatments [21–23]. The immunological pathway activation could be in two ways: systemic or local. The first one utilizes systemic cytokine administration, whereas the latter employs immune checkpoint- or small molecule-inhibitors to manipulate the TME [24, 25].

The use of organic and inorganic nanomaterials refined the efficacy of cancer immunotherapy (Figure 1). Specifically, 1–200 nm size particles possess unique physiochemical properties. The potency of nanomaterials in cancer diagnosis and therapy has been demonstrated by many research groups [26–28]. Surface-modified nanomaterials selectively target and invade tumour tissues. The molecules with low bio-availability and bio-compatibility reside in the inner core of surface-modified nanomaterials, thereby exhibit extended blood retention time, and reduced renal clearance. All these ideal characteristics are beneficial to treat widely distributed tumours with minimal toxicity [29–31]. Nanomaterials efficiently deliver molecules such as peptide [32], antigen [33], antibody [34], and whole-cell membrane [35]. These molecules often selectively inhibit or block various checkpoints [36] on immune cells and improve the efficacy of cancer immunotherapy. This review elucidates the starring role of nanomaterials and their augmentation in cancer immunotherapy. Besides, the physical characteristics of the immune system and cancer microenvironment are discussed. These characteristics are proven to interact with the biodistribution of nanocarriers. In the end, a few successful and on-going clinical trials of immunotherapy are summarized.

Immunotherapy has been developed as an alternative strategy against cancer during the past decade. Immunotherapy serves to prevent metastasis and to improve the quality of life of affected individuals. Immunotherapy can stimulate or inhibit various components of the immune system. These components include lymphokines, vaccines, effector cells, and antibodies [37]. The concept of immune surveillance is based on the early demolition of abnormal cells by the immune system, which prevents the development of tumour cells [37]. Therefore, lack of immune surveillance critically contributes to the development of the tumour. It may be accompanied by evasion of tumour cells from the immune surveillance system and an escape from T-cell-specific immunity [38, 39].

The use of CAR-T cells against the progression of many solid tumours such as colorectal cancer (CRC) has been evident by various reports. For instance, the anti-fluorescein-5-isothiocyanate (FITC)-labelled CAR-T cells were used to treat epidermal growth factor receptor (EGFR)-positive CRC. Besides, FITC-labelled cetuximab was used to treat EGFR-positive CRC [40]. Engineered cytokine-induced killer (CIK) cells with CAR targeting carcinoembryonic antigen (CEA) was developed from blood lymphocytes from CRC patients. The CAR-modified CIK cells proved for their specific selectivity in targeting autologous CRC [41]. In addition, four clinical trials were carried out by different research groups targeting HER2 [42], tumor-associated glycoprotein (TAG)-72 [43], CEA [44], or carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) [45] by CAR-T cells.

EpCAM (CD326), a 40 kDa transmembrane glycoprotein, was overexpressed in many solid tumours and less-expressed in normal epithelial cells [46]. Therefore, EpCAM coupled second-generation CAR was developed and transduced into NK-92 cells by lentiviral vectors. The cytotoxicity and immunological effect of CAR-NK-92 cells were tested against colon cancer in vitro [47]. In another study, CAR-NK-92 cells were combined with regorafenib and used against EpCAM-positive tumour xenografts. The combination therapy was more effective than individual treatment (regorafenib or CAR-NK-92 cells) [47].

Even though CAR T-cell therapy showed remarkable clinical efficiency against solid tumours, the toxicity and the complexity of production make it a less-preferred approach in clinical settings. In general, CAR-T cells are prepared based on individual patient samples that imply the complexity of the process and expensive nature [48–50]. Therefore, an effective allogenic product is warranted to overcome these limitations. One such potential model is modified CAR-NK cells [10]. The dose-dependent safety and efficacy of CAR-NK cells were evaluated against CD19 positive cancer cells in clinical trials (phases 1 and 2). In a total of 11 patients, eight patients treated with CAR-NK cells have shown positive responses. Moreover, seven of them [4 with lymphoma and 3 with chronic lymphocytic leukemia (CLL)] showed complete remission. All these changes were noticed within 30 days of infusion but with different doses. Crucially, the administration of CAR-NK cells did not provoke adverse conditions (cytokine release syndrome, neurotoxicity, etc.) [10].

Modified CAR-T or CAR-NK extend new opportunities for cancer treatment [47]. NK cells contribute to cancer immune surveillance [51] through their inherent cytotoxicity and stimulation of cell surface receptors. Besides, NK cells adapt T-cell mediated anticancer immune responses by secreting cytokines and chemokines that trigger inflammatory responses [52]. Various scientific studies recognized the role of NK cells in cancer immune surveillance. NK cell-based adaptive immunotherapy is one of the rapidly developing fields. Efforts are in progress in refining the strategies to alternate CAR-engineered effector cells with NK cells [53, 54]. Furthermore, the transplantation of NK cells to a human leukocyte antigen (HLA)-mismatched recipient is considered reliable [55].

NK cells can activate both innate and adaptive immune systems to defend against both infections and cancer. NK cells are highly preferred in cancer immunotherapy [56] because of the following reasons: NK cells destroy cancer cells without antigen-specific stimulation [57]; NK cells secrete various cytokines [e.g., tumor necrosis factor-alpha (TNF-α)] to regulate the immune response [58]; NK cells aid in the maturation of APCs, which further activate T cells to destroy tumour cells [59]. NK cells with the help of their membrane proteins [e.g., receptor activator of nuclear factor (NF)-kB-ligand (RANKL) or DNAX accessory molecule-1 (DNAM-1)], induce the polarization of M1-macrophage and target tumour cells [60–62]. NK cells directly activate anti-tumour immunity by eradicating the malignant cells; besides, NK cells exert tumour-specific adaptive immune response through crosstalk with dendritic cells [63]. NK cells control dendritic cells (DCs) maturation, which mediates T-cell activation [64]. Despite, DCs support the direct anti-tumour activity of NK cells [65]. However, owing to the immunosuppressive activity of the tumour, the function of NK cells in cancer patients is attenuated, which is, discouraging. Peripheral blood- and cord blood-derived NK cells from donors are used in lymphocyte infusions and to generate less-expensive genetically modified NK cells [66, 67]. Heterogeneously expressed CAR-target antigens of NK cells attack tumours. Besides, the inherent cytotoxic property of NK cells can act as a counterpart to CAR-mediated destructive effects on cancer cells [63]. Taken together, the identification and blocking of immune checkpoints of NK cells and their tumour-specific redirection can be beneficial for both malignant and solid tumour patients. Given the advantages, these approaches are used in the development of therapeutics (CAR-T-cells- and CAR-NK-cells-based) for malignant glioma. In a pre-clinical mice model, transduced NK cells with anti-CD19 CAR, interleukin-15, and inducible caspase 9 showed improved anti-tumour activity compared to non-transduced NK cells (control) [67].

Nanomaterial-based cancer immunotherapy poses more advantages than chemo- and immune-therapies. Due to their unique characters such as variable size, shape, charge, elasticity, and capability as an excipient, nanomaterials are highly preferred [68, 69]. Specifically, the surface engineered-nanomaterials are useful in cancer immunotherapy to target specific receptors and transport peptides, antigens, adjuvants, antibodies, and small molecules [70]. Pharmacokinetics and pharmacodynamics studies revealed the enhancement stability, bioavailability, circulation, half-life time, and therapeutic efficacy of a drug or molecule when combined with a nanocarrier. Cancer immunotherapy utilizes both organic and inorganic nanomaterials. However, organic nanomaterials are preferred carrier molecules over inorganic nanomaterials due to their biocompatibility.

The capacity of liposomes to function as carriers for the delivery of drugs and vaccines has been investigated. Positively, the amphiphilic nature of liposomes effectively entraps both hydrophobic and hydrophilic molecules [71]. Besides, liposomes (positively-charged) exhibited immunostimulatory properties via activation of pro-inflammatory and pro-apoptotic pathways [72]. The activated pathways thus lead to the generation of reactive oxygen species (ROS) [73], the elevation of the expression of co-stimulatory molecules [74], and secretion of chemokines and cytokines. Polyethyleme glycol (PEG) coating to large liposomes (> 100 nm) facilitates the effective uptake by the lymph node (LN) [75]. A recent study reported the formulation of α-galactosylceramide (α-GalCer; an adjuvant) and tyrosine-related protein 2 (TRP2) antigen-loaded cationic liposomes prevented the tumour progression through cytotoxic T-cell response (CD8⁺). α-GalCer is a potent activator of NK-, and T-cells, as well as TRP2 is a melanocyte lineage-antigen expressed by malignant melanoma cells. Intravenous adjuvant and antigen delivery were successful using liposomes, which resulted in enhanced secretion of interferon-gamma (IFN-γ), activation of cytotoxic T-cells, and reduction of tumour survival. In addition, PEG-coating reduced the cytotoxicity of cationic liposomes at intravenous delivery [33]. The delivery of antigens using cationic liposomes in the intravenous system also facilitates the accumulation in the spleen and phagocytosis by CD8⁺ DCs [76, 77].

Plasma membrane vesicle (PMV) derived from a live source (cultivated cells, isolated tissues, etc.) function as a tumour-antigen delivery system. The plasma membrane-derived vesicles also contain lipid bilayers, which make them amenable for surface modification and to carry antigens. For instance, PMVs derived from breast cancer cells have delivered glycosylphosphatidylinositol (GPI)-HER-2 antigens and triggered both cellular and humoral immunity. It eventually resulted in delayed tumour growth and partial regression of established tumours [78]. In cancer cells, GPI-B7-1 or GPI-IL-12 induced T-cell proliferation. Besides, PMVs displaying GPI-B7-1 provoked tumour-specific T-cell-mediated cytotoxicity and protection [79].

Viral mimicking protein-based nanomaterials elicited the immune response under the TME. Also, non-viral pyruvate dehydrogenase E2 protein-nanoparticles exhibited biomimetic properties in cancer vaccine delivery. In melanoma glycoprotein 100 (gp100)-epitope, and cytosine-phosphate-guanine (CpG)-oligonucleotide conjugation to E2 nanoparticles resulted in the antigen-specific cytotoxic-T-cell proliferation and IFN-γ secretion by 1.5-fold and 5-fold, respectively [80]. Gardasil is the first clinically approved virus-like nanoparticle-based vaccine; besides, many other protein-based nanoparticulate assemblies have been suggested as vaccines that boost T-cell responses against various infectious diseases [81].

Microbubbles are used for the delivery of tumour antigen to DCs by the sonoporation method. The efficacy of antigen mRNA and TriMix mRNA inducing immune response have been evaluated in vivo. The co-delivery of these mRNA modulated the function of DCs, and T cell phenotype [82]. Besides, the delivery of TriMix with TAA antigens leads to the induction of durable anti-tumour responses [83].

Mannose receptor targeting, ovalbumin-based dextran (DEX) nanoparticles have been reported for the induction of ovalbumin (OVA) peptide-specific CD4⁺ and CD8⁺ T-cell proliferation both in vitro and in vivo. This OVA-DEX-based nano vaccine triggered humoral immune response [immunoglobulin G (IgG)1 > IgG2a], delayed-type hypersensitivity responses, and cytotoxic CD8⁺ T cells in vivo [84]. Acetylated DEX (Ac-DEX) nanoparticles with acetal-protecting groups were reported as immunotherapeutic agents. These agents possess the potential to elicit both major histocompatibility complex (MHC) I and MHC II presentation. Broaders et al. [85] loaded OVA antigen to Ac-DEX nanoparticles to enhance MHC presentation. Surprisingly, in the Ac-DEX nanoparticles-treated cells, the presentation of both MHC class I and II molecules ware observed.

Apart from organic materials, inorganic nanomaterials also demonstrated their potential for cancer immunotherapy. Gold nanoparticles were synthesized using melanoma B16F10 cells (AuNP@B16F10) and characterized. The particle size was 30 nm, and the membrane thickness was between 4 and 6 nm. In order to promote the antigen-presenting capability and to improve biocompatibility, DC-derived gold nanoparticles were synthesized (AuNP@DCB16F10) using the same cells. This complex (AuNP@DCB16F10) was capable of promoting the maturation of DCs, cytokine secretion, and T cell activation. Altogether, this study revealed the development of anti-tumour immunity and prevention of tumour metastasis and relapse [86].

Iron- and zinc-oxide based multifunctional core-shell nanoparticles deliver the CEA into DCs. The rapid uptake of nanoparticles by DCs was evidenced by confocal microscopy in vitro and magnetic resonance imaging in vivo. The antigen (CEA specific cellular immunity was demonstrated in nanoparticle complex-immunized C57BL/6 mice, in that a significant reduction in tumour growth was witnessed, compared to control. Besides, tumour-bearing mice showed delayed tumour growth and sustained survival, together evidenced the efficacy of antigen delivery by nanoparticle complex [87]. A recent report demonstrated the activation to DCs by mesoporous silica. The doping of silica with gold nanoparticles (Au@XL-MSNs) aided in the delivering of a high amount of CpG-oligodeoxynucleotides (ODNs) to the tumour site. Moreover, Au@XL-MSNs were effectively internalized in bone-marrow-derived dendritic cells (BMDCs) that increased the expression of co-stimulatory molecules and pro-inflammatory cytokines compared to soluble CpG-ODNs [88]. In this sense, we have summarized the list of fabricated nanomaterials used in cancer immunotherapy (Table 1).

Effective and site-specific delivery of immune-modulating agents are key characteristics of a vaccine; therefore, these characteristics are considered in the nano-vaccine formulations [89]. It is reported that peptides and proteins in their soluble form induce low level of immune response due to the poor uptake by APC. Furthermore, peptides and proteins elicit non-specific interactions and susceptible to enzymatic degradations. Finally, the antigen presentation process is hampered, and uptake of antigen by immune cells is diverted [90]. Conversely, delivery of peptides and proteins with organic nanomaterials such as liposomes and polymeric carriers protect them from enzymatic degradation and enhance their uptake by APC [91]. Nanomaterials guard the encapsulated or immobilized materials (antigen/adjuvant) from the renal clearance and surrounding biological environment. Further, it enhances the half-life, reduces toxicity, endorses delivery to APCs, and sometimes, directly activates the TAA specific T-cells [92]. For instance, antigens and adjuvants-encapsulated nanomaterials enhanced the activation of T- and B-cell immune response compared to soluble antigens. The delivery of antigens to APCs by nanoparticles provoked an adaptive immune response, as evidenced in vivo. Kasturi et al. [93] revealed that a biodegradable synthetic, ~ 300 nm-sized polymer (PLGA) encapsulated with Toll-like receptor (TLR) ligands [monophosphoryl lipid A (MPLA); TLR4 ligand and R837; TLR7 ligand] and antigen used in immunization of mice, improved the antibody and T-cell responses compared to control (soluble antigen plus MPL and R837). The significance is that the delivery of antigen or peptide with nanoparticles resemble the immunogenicity of live viral vaccines [94].

The APCs (e.g., DC) play a crucial role in inducing adaptive immune response, which involves capturing, processing, and presentation of antigens [95]. DC vaccination implicates strong T-cell responses against both self and foreign antigens [32]. The delivery of peptides or proteins by nanoparticles enhanced the antigen uptake property of DCs and aided in the sustained release of antigens by nanocarriers that eventually facilitated both cellular and humoral responses [90]. In DCs, the uptake of soluble and particulate antigens is mediated by pinocytosis and phagocytosis, respectively. However, phagocytosis potentially induces a higher level of immune response compared to pinocytosis [96]. The effective uptake of apoptotic bodies, latex particles, liposomes by DCs was reported earlier [97]. PLGA nanoparticles loaded with a human MUC1 lipopeptide (2,765 Da-sized cancer-associated antigen [BLP25; (ε-palmitoyl) G], and MPLA were delivered to murine bone marrow-derived DCs in vitro. Ultimately, the PLGA nanoparticles were phagocytised and enhanced the expression of MHC class II and CD 86 molecules compared to control [32]. PLGA nanoparticles were also delivered to cord blood-derived DCs [98]. Similarly, polystyrene-beads were delivered to monocyte-derived DCs [99].

Overexpression of HER-2 receptor tyrosine kinase has been observed in diverse human malignancies such as breast, ovarian, gastric, non-small cell lung, and salivary gland cancers. HER-2 is thus associated with the prognosis of malignant cells [100]. In this purview, peptide vaccination has induced T-cell responses (both CD4⁺ and CD8⁺ receptor-mediated) against HER-2 [101]. Further, a humanized HER2-specific monoclonal antibody named Hercpetin is clinically approved for HER2-targeted immunotherapy [102]. In BALB/c mice, scFv^CD11c-HER2 fusion protein with DC-activating CpG oligonucleotides (scFv^CD11c-HER2_CpG) was administered. Consequently, HER2-specific immune response was initiated, which hampered the growth of HER2-expressing tumour cells [103]. Plant virus [icosahedral cowpea mosaic virus (CPMV) and filamentous potato virus X (PVX)]-based nanoparticles were reported to deliver HER2 epitopes in cancer immunotherapy (HER2⁺ malignant cancer). Upon administration, CPMV and PVX nanoparticles were phagocytised by DCs, which lead to the accumulation of nanoparticles in draining LNs and stimulation of HER2-specific humoral response [104].

The delivery of various antigens (CEA and galectin-3) was evidenced in the cancer microenvironment [105]. The surface-coating of nanoparticles using cancer cell membrane resulted in biomimetic nanomaterials. These particles exhibit inherited homologous targeting potential [106]. The use of cell membranes for the functionalization of nanoparticles offers a novel approach and the unique advantage of holding a complete copy of antigenic structure and functions [107]. A series of cell membrane-camouflaged nanomaterials from source cells have been demonstrated for their inherited features. A few examples are as follow: nanoparticles coated with neutrophil cell membrane neutralize proinflammatory cytokines [108]; nanomaterials camouflaged with platelet membrane damaged the vasculature and pathogens [109]; leukocyte-membrane coated microspheres pose the ability to cross the endothelium [110]; and red blood cell (RBC) membrane-encrusted particles exhibit extended circulation time [111]. Nanomaterials with membrane-bound tumour antigens signal the immune system to recognize and combat cancer [112]. Further, cancer cell membrane mimicking particulate vectors surface-functionalized with antigens have been fabricated to enhance vaccine potency [113, 114].

Cell membrane immunotherapy helps to stimulate the immune systems against tumours. For instance, NK cells elicit M1-macrophage polarization that induced the immune system. NK-cell membrane coated nanoparticles cloaked with photosensitizer 4,4′,4′′,4′′′-(porphine-5,10,15,20-tetrayl) tetrakis (benzoic acid) (TCPP)-loaded NPs were used to eliminate primary and metastatic tumours in vivo. The TCPP-coated nanoparticles induced cancer cell death via photodynamic therapy. [115].

PLGA nanoparticles are loaded with R837 (TLR7 agonist) and coated with membranes of B16-OVA cancer cells. Besides, the surface modification of the nanoparticles (NP-R@M-M) was achieved with the mannose adopting the lipid-anchoring method. The surface modification enhanced the internalization of the particles in DCs. Upon intradermal injection, these particles efficiently migrated into draining LNs and prompted tumour-specific immune responses. The developed NP-R@M-M nanoparticles demonstrated as a prophylactic vaccine to defend against cancer cells in mice. Also, these particles, in combination with anti-PD-1 checkpoint inhibitors, exhibited as a therapeutic vaccine to combat melanoma progression [116].

B16-F10 mouse melanoma cell membranes have been used to camouflage PLGA nanoparticles. Cancer cell membrane nanoparticles (CCNPs) possess an antigenic exterior that closely resembles a source of cancer cells. CCNPs, along with TAA, immunological adjuvants, are effectively delivered to APCs to promote antitumour response [116]. Since the coated cell membrane consists of a cell adhesion molecule identical to the source cell, it reflects a homotypic binding mechanism that can be used for cell-specific targeting [105].

Recently a biomimetic nanoparticle platform has been reported to stimulate T-cells directly in the absence of APCs. Engineering aAPCs provide control over antigen presentation since the cells can replace endogenous counterparts [117]. Both living cells and cell line can be engineered to express suitable MHC and co-stimulatory markers on their surface. These engineered aAPCs have been demonstrated to engage and activate T cells. In recent times, developing particulate APCs have paid greater attention [118]. Especially, nano-scaled APCs hold many advantages. It enhances lymphatic transport when administrated subcutaneously [119]. The wild-type B16-F10 (B16-WT) murine melanoma cell line has been chosen to express two different antigens; OVA and CD80. The first is a model antigen, and the latter is a co-stimulatory marker, which engages CD28 receptor of T-cells. The membranes of engineered cancer cells were separated and cloaked on PLGA nanoparticles. The double knock-in nanoparticle formulation acquires endogenous signals for T cell stimulation and is demonstrated to control tumour growth in murine models [35].

Checkpoint inhibitors are either made up of proteins or monoclonal antibodies. These inhibitors downregulate the immune system by CTLA-4 and PD-1 signalling pathways and support the cancer cells [120]. In this sense, anti-CTLA-4 and anti-PD-1/PD-L1 were proposed as checkpoint inhibitors of various malignancies such as Hodgkin’s lymphoma [121], NSCLC [122], CRC [123], bladder cancer [124], and urinary tract cancer [125]. PD-1 is found on the cell surface of both activated T and B, whereas PD-L1 is a transmembrane protein [126]. The interaction led to an immunosuppressive environment, in which downregulation of T regulatory cells and inhibition of antigen-specific immune cells is crucial. These usual immune processes maintain the homeostasis of the immune system and to prevent autoimmunity complications. However, some metastatic tumours evade immune detection by altering the expression of PD-1/PD-L1 [127]. Therefore, inhibiting immunosuppression reaction by blocking the protein (PD-L1 or PD-1) is considered a potent strategy for downregulating tumour cell prognosis.

Neuropilin-1 (Nrp 1) is a key receptor of regulatory T (Treg) cells. Hybrid nanoparticles surface decorated with tLyp1 peptide has been reported to target Nrp1. The high-affinity binding of tLyp1 with Nrp 1 of Treg leads to the suppression of the function of Treg cells by tLyp1-hNPs. This anti-CTLA4-based immune-checkpoint blockade approach bolsters T cell response in the cancer microenvironment and potentiates tumour demolition [36].

Co-encapsulated PLGA nanoparticles (ICG, photothermal agent) and TLR-7 agonist imiquimod (R837); PLGA-PEG-ICG-R837] along with intravenous administration of anti-CTLA4 were used in the treatment of mammary carcinoma 4T1 (mice model). The fabricated nanoparticles exhibited vaccine-like properties against primary tumours by expressing tumour associated antigens. Also, intravenous administration of anti-CTLA4 has generated immunological responses that inhibit metastasis and prognosis of tumour. ICG-based photothermal therapy was used to abolish the tumours in vivo. Autopsy results of tumour-draining LNs revealed the infiltration of activated and matured DCs at the tumour site [128].

Nanoparticle mediated activation of LN resident DCs along with co-administration of anti-PD-L1 was often proved in long-term control of metastatic tumours. In brief, micellar-based, pathogen mimicking nanoparticles were loaded with TLR4-agonist and OVA model antigen against metastatic tumours. Bacteria (Xanthomonas campestris and E. coli)-derived cubic iron oxide nanoparticles possess lipooligosaccharides (TLR4-agonist) and suitable for in vivo trafficking and multimodal imaging. These particles induce M1 macrophage polarization, therefore used in DC-based vaccination. These nano-based vaccines exhibited enhanced protection against aggressive B16-F10 murine melanomas and abolition of PD-L1 expression melanomas, with 100% tumour rejection [129].

Small molecules targeting specific pathways or cells with a capability of immune modulation are anticipated to improve the efficacy in cancer immunotherapy. Small molecules are well characterized for their systemic administration and toxic effects. Hence, they are amenable for both extracellular and intracellular targets. These molecules can influence the molecular pathways that regulate immune tolerance and suppression towards effective antitumour response [130]. As mentioned earlier, the PD-1/PD-L1 axis inhibits TCR and CD28 signalling is a potential target for cancer immunotherapy; at present, antibodies are used to target the axis. However, small-molecules also may be used for targeting the PD-1/PD-L1 axis. Imiquimod, an imidazoquinoline derivative, commonly prescribed for genital warts is the first small-molecule drug approved by the FDA for the treatment of basal cell carcinoma [131]. The small-molecules such as BMS (BMS-103, -142, -200, -202, -242, -1001, and -1166), that act through a novel dimer-locking mechanism has shown promising results in vitro [132, 133]. Arginase is another promising target in the TME. ARG I inhibitor CB-1158 (INCB001158), inhibited the myeloid cell mediated immune suppression of T-cell proliferation in T-cell cocultures, that reducing tumour growth in different mouse models [76]. Compared to antibodies, small-molecules can penetrate tissues easily; therefore, they can targeted both extracellular and intracellular to endorse antitumour immunity [130]. Small-molecules that studied for cancer immunotherapy and under clinical trials are reviewed in detailed by Zanden et al. [130]. Though, various small-molecules targeting the PD-1/PD-L1 axis are under focus, their development lagging behind the efficiency of monoclonal antibodys (mAbs) due to disputes in formulating molecules to occupy the hydrophobic PD-1/PD-L1 interface with high affinity [130].

Nanomaterials were employed in the diagnosis and used as drugs to target various diseases including, metastatic cancer. Nanomaterials are conjugated with drugs that have poor bioavailability. Besides, improved tissue selectivity, enhanced protection for payload, reduced renal clearance, and extended circulation period are considered as merits for nanomaterials. However, delivery of molecules such as peptides, proteins, antigens, antibodies, and nucleic acids, produce side effects. However, the characteristics of these molecules are different from pre- to post-encapsulation. In this sense, predicting the pharmacokinetics property and assessment of biodistribution efficiency is crucial. It helps to determine the efficacy and side effects of a given drug [134]. The pharmacokinetics of nanoparticles were accessed by accounting various chemical and physical properties (size, charge, surface chemistry, etc.).

When nanomaterials administered in vivo, a variety of serum proteins readily bind to the surface of nanoparticles that enhances the engulfment property of macrophage and results in significant loss of payload in the circulation [135]. The substance that binds to the nanoparticle is called opsonin, which, in turn, mediates the clearance of nanomaterials by macrophage through the reticuloendothelial system (RES). In this purview, reduction of protein binding is significant while developing nanoparticles with an extended circulation time [134]. The potential of nanoparticles and their biological applications is not only agreed by the physiochemical properties but also based on the interactions with the surrounding molecules. However, nanomaterials, in some circumstances, alter the function of the immune system and provoke significant health risks. Therefore, the safety of a nanoparticle (even for a non-toxic nanomaterial) is a potential human health concern [136]. Previous studies demonstrated that nanoparticles either induce or inhibit the innate immune response [137]. The innate immune system works at the nanoscale in that the size of nanoparticles resembles viruses. The immune system thus considers nanoparticles as foreign material (like viruses) and provokes the immune response in a systematic way [138]. Specifically, the interaction of immune cells with nanoparticles causes phase transformations, particle aggregation, surface reconstruction, and dissolution. These processes eventually affect the reactivity, bioavailability, and pharmacokinetic properties of the nanoparticles [139]. The altered characteristics may provoke immunotoxic effects. Therefore, a guided strategy is recommended to fabricate the multi-purpose nanoparticles.

Cancer immunotherapy is a sought-after method in the treatment of metastatic tumours. Yet, the challenges in the clinical progress of immunotherapy are to be addressed. The cancer-related characteristics vary in patients and are determined by the surrounding microenvironment [140]. Moreover, some tumours are arising followed by chronic inflammatory conditions, whereas other malignancies destabilize or co-opt immune responses as part of their progression [140]. Every single process, such as screening of drugs, determine the drug delivery and dose, schedule, and administration of drugs, and revealing the molecular mechanism, are pivotal in cancer therapy. The use of animal models has helped to appropriate immunotherapy (e.g., CTLA-4 and PD-L1/PD-1 blockade) [141, 142]. Despite various animal models of cancer, a great degree of disparity exist between the immunology of human cancer and animal models [143, 144]. For instance, the composition of APCs, T- and B-cells in the TME, presence of tumour antigens, and complexity of immune cell modulation or suppression differ between human cancers and animal models of cancer [145, 146]. The complications of cancer immunotherapy have been discussed in detail by Hegde and Chen [140]. Considering these challenges would help to improve pre-clinical models, clinical biomarkers, organ-specific immunity, and so on.

Clinical trials are successful in screening successful anti-cancer drugs. In the past decade, CAR T-cell based clinical trials exhibited significant therapeutic potential and are, therefore, approved by US-FDA. The CAR T-cell based immunotherapy is a hallmark in cancer treatment. Immunotherapy is advantageous in many ways; it exhibited prolonged and comprehensive retardation in patients and demonstrated to have potential in manipulating the immune system against cancer [147, 148]. The resilient success of the immunotherapeutic approach leads to several clinical against metastatic tumours. The trials investigated various treatment modalities (single or combination of drugs). In the context of cancer immunotherapy, we have summarized a list of drugs, their clinical trials, stages, and approval code in Table 2. For example, nivolumab (humanized mAb and PD-1 checkpoint inhibitor) and lpilimumab (fully human mAb and CTLA-4 checkpoint inhibitor) were primitively reported as immunotherapeutic agents against metastatic melanoma. It was a randomized, double-blind, and phase 3 study conducted with metastatic melanoma patients. The combination of nivolumab and ipilimumab were resulted in progression-free survival [34]. Albeit CAR T therapies are reportedly successful against haematological cancer, their impact on solid epithelial based cancers was not significant [149].

Metal nanoparticle-based, immune checkpoint-targeting, combinational therapy was popular against advanced cancer stages. In an open-label, phase I trial, NBTXR3 with radio- and anti-PD-1 therapies (NCT03589339), the anti-tumour response, safety, feasibility, and kinetic profile of the drug were considered as outcome measures within the expected time frame (24 months) [150].

A monoclonal antibody (nivolumab; an anti-PD-1 antibody, and ipilimumab; an anti-CTLA-4 antibody) was combined with a synthetic drug (anthracycline and cyclophosphamide) to determine the efficacy of combinational therapy in a phase IIb trial (ICON; NCT03409198). Anthracycline is considered immunogenic, and low-dose cyclophosphamide is used to counteract immunosuppressive cells. This study was approved in 2018 for immunogenic chemotherapy [151].

Sipuleucel-T was used to design a therapeutic cancer vaccine. The formulation consists of autologous peripheral-blood mononuclear cells (PBMCs) and APCs, both of which were activated with recombinant fusion protein (PA2024) ex vivo. PA2024 was a combination of prostate antigen and prostatic acid phosphatase; both were fused to granulocyte-macrophage colony-stimulating factor. In a double-blind, randomized, placebo-controlled, phase 3 trial, 512 patients were assigned to receive either Sipuleucel-T (341 patients) or placebo (171 patients; NCT00065442). Consequently, men with metastatic castration-resistant prostate cancer showed prolonged survival. However, adverse side effects (chills, fever, and headache) were reported in sipuleucel-T treated patients [152].

Polymeric nanoparticles loaded with Cetuximab and decorated with a somatostatin analogue. Cetuximab is a chimeric monoclonal antibody formulated against EGFR-targeting cancer cells. When administered orally, the polymeric nanoparticles released the loaded drugs using ethylcellulose polymer and are stable at above the pH 6.8. The nanoparticles protect the drug (Cetuximab) even at extreme acidic pH (1.5). In CRC cells, somatostatin receptor (SSTR) is overexpressed. Therefore, the formulated nanoparticles selectively target the cancer cells octreotide (an SSTR agonist). Besides, the pharmacokinetic parameters of Cetuximab were measured for 12 months (NCT03774680). Nanomedicine is thus a potential immunotherapeutic agent, as demonstrated by a plethora of experiments and clinical trials. Further, many conceptual and evidence-based approaches are under clinical trials, which become worthwhile soon.

In this review, various insights are covered with respect to conventional cancer immunotherapy, nanomaterials under investigation (pre-clinical and phase trials), and the mode of action of different nanomaterials on immune system. Cancer immunotherapy, in part, solicits the immune system to manipulate the immunosurveillance. Various parameters in the TME may either render support or hamper the immunotherapy. The presence and absence of Treg cells, tumour associated macrophages, and expression of TAA are considered pivotal. Our viewpoint of previous studies proposes nanomaterials as a promising entity to enhance cancer immunotherapy. Specifically, biological nanomaterials reinforced the efficacy of immunotherapy because of their unique characteristics and functions. The nanoparticle can be used as an immune stimulator or adjuvant (to deliver or presenting peptide, specific antigen, or whole cell membrane). Put together, the nanoparticles are useful to target checkpoint inhibitors and to reverse the immunosuppressive condition of TME. The outcome of pre-clinical and clinical trials endowed the motivation for clinical testing of diverse concepts. The studies and examples conversed herein may shed light on novel possibilities and approaches against malignancies soon. However, persuading challenges (inadequate knowledge of patient and TME, lack of impersonating animal models) in cancer immunotherapy need to be overcome. These facts would expand the field of immune-oncology and facilitate the venturing of cancer immunotherapy into a new era.